{
    "clinical_study": {
        "@rank": "104043", 
        "arm_group": {
            "arm_group_label": "Treatment", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "In this Phase 1 trial of retinal pigment epithelium (RPE) replacement, the aim will be to\n      evaluate the safety and feasibility/efficacy of treating subjects with wet age-related\n      macular degeneration (AMD) in whom there is rapidly progressing vision loss"
        }, 
        "brief_title": "A Study Of Implantation Of Human Embryonic Stem Cell Derived Retinal Pigment Epithelium In Subjects With Acute Wet Age Related Macular Degeneration And Recent Rapid Vision Decline", 
        "completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Age Related Macular Degeneration", 
        "condition_browse": {
            "mesh_term": "Macular Degeneration"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and /or post-menopausal female subjects aged 61 years or above.\n\n          -  Diagnosis of wet Age-related Macular Degeneration (AMD) plus rapid recent vision\n             decline\n\n          -  An informed consent document signed and dated by the subject or a legal\n             representative.\n\n        Exclusion Criteria:\n\n          -  Pregnant females; breastfeeding females; and females of childbearing potential.\n\n          -  Treatment with an investigational drug within 30 days (or as determined by the local\n             requirement, whichever is longer) or 5 half-lives preceding the first dose of study\n             medication.\n\n          -  Current or previous significant other ocular disease in the study eye, as determined\n             by the investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "61 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01691261", 
            "org_study_id": "B4711001"
        }, 
        "intervention": {
            "arm_group_label": "Treatment", 
            "description": "PF-05206388 will be provided as a Retinal Pigment Epithelium living tissue equivalent for intraocular use in the form of a monolayer of Retinal Pigmented Epithelial (RPE) cells immobilized on a polyester membrane. The membrane is approximately 6 mm x 3 mm and will contain a confluent layer of RPE cells, at a nominal dose of 17 mm2. The implant is intended to be life-long.", 
            "intervention_name": "PF-05206388", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 22, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B4711001&StudyName=A%20Study%20Of%20Implantation%20Of%20Human%20Embryonic%20Stem%20Cell%20Derived%20Retinal%20Pigment%20Epithelium%20In%20Subjects%20With%20Acute%20Wet%20Age%20Related%20Macular"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 1, Open-Label, Safety And Feasibility Study Of Implantation Of PF-05206388 (Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE) Living Tissue Equivalent) In Subjects With Acute Wet Age Related Macular Degeneration And Recent Rapid Vision Decline", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence and severity of adverse events.", 
                "safety_issue": "Yes", 
                "time_frame": "52 weeks"
            }, 
            {
                "measure": "Change in baseline in ETDRS best corrected visual acuity (BCVA) - Proportion of subjects with an improvement of 15 letters or more at Week 24.", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01691261"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in baseline in ETDRS best corrected visual acuity (BCVA) - Proportion of subjects with an impovement of 15 letters or more", 
                "safety_issue": "No", 
                "time_frame": "at Weeks 1,2,4,8, 12,16, 36 & 52."
            }, 
            {
                "measure": "Mean change of best corrected visual acuity (BCVA) from baseline by study visit.", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "measure": "Position of PF-05206388 by serial biomicroscopic evaluation.", 
                "safety_issue": "No", 
                "time_frame": "at Weeks 1, 2, 4,8, 10, 12, 16, 24, 36 and 52"
            }, 
            {
                "measure": "Position and presence of pigmented  Retinal Pigment Epithelium cells by serial fundus photography and SLO autofluorescence.", 
                "safety_issue": "No", 
                "time_frame": "at Weeks 4, 6, 10, 12, 16, 24, 36 and 52"
            }, 
            {
                "measure": "Placement of PF-05206388 by serial spectral domain Ocular CoherenceTomography (OCT) scan", 
                "safety_issue": "No", 
                "time_frame": "at Weeks 4, 8, 12, 16, 24, 36 and 52."
            }, 
            {
                "measure": "Change in liver and renal function by blood tests and liver ultrasound .", 
                "safety_issue": "Yes", 
                "time_frame": "at Weeks 24 and 52"
            }, 
            {
                "measure": "Change in leakage or perfusion in normal fundal vasculature and presence of abnormal vasculature  by fundus fluorescein angiography.", 
                "safety_issue": "Yes", 
                "time_frame": "at Weeks 4, 8, 12, 24 and 52"
            }, 
            {
                "measure": "Change in central 30 degree of visual function  by Humphrey Field test.", 
                "safety_issue": "No", 
                "time_frame": "at Weeks 4, 8, 12, 24 and 52"
            }, 
            {
                "measure": "Evidence of diffuse retinal and RPE toxicity by full field ERG and EOG.", 
                "safety_issue": "Yes", 
                "time_frame": "at Weeks 12 and 52"
            }, 
            {
                "measure": "Photoreceptor survival (indirect indication of RPE survival)  by Adaptive Optics.", 
                "safety_issue": "No", 
                "time_frame": "at Weeks 16, 24, 36 and 52"
            }, 
            {
                "measure": "Functional survival of retinal photoreceptors  by Nidekmicroperimetry over PF-05206388.", 
                "safety_issue": "No", 
                "time_frame": "at Weeks 4, 16, 36 and 52"
            }, 
            {
                "measure": "Change in reading speed by Minnesota (MN) Read test.", 
                "safety_issue": "No", 
                "time_frame": "at Weeks 4, 8, 16, 24, 36 and 52"
            }, 
            {
                "measure": "Change in thickness of RPE layer by B-mode orbital ultrasound.", 
                "safety_issue": "Yes", 
                "time_frame": "at Weeks 4, 8, 16, 24, 36 and 52"
            }, 
            {
                "measure": "Detection of alloactive T-cells and alloreactive antibodies (blood) .", 
                "safety_issue": "No", 
                "time_frame": "at Weeks 2, 4, 8 12, 24 and 52"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "collaborator": {
                "agency": "University College, London", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}